Frank Leonard compensation by year
NovoCure Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $475,000 | $525,000 | $570,000 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $2,866,517 | $3,333,317 | $4,999,993 |
| Option awards | $1,435,196 | $1,670,829 | $1,001,020 |
| Non-equity incentive | $253,650 | $283,500 | $389,644 |
| Pension and deferred compensation | — | $0 | $0 |
| All other | $8,874 | $11,284 | $14,672 |
| Total | $5,039,237 | $5,823,930 | $6,975,329 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NovoCure Ltd DEF 14A filed April 20, 2026, accession 0001645113-26-000033, and prior-year filings.
How this page was built: the NovoCure Ltd filed document, accession 0001645113-26-000033. Every figure is read from that document and cited to the page and table it appears in. Filed April 20, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 179,426 | $2,319,978 | — |
| PSU | 102,249 | $1,322,080 | — |
| RSU | 68,166 | $881,386 | — |
| RSU | 54,975 | $710,827 | — |
| PSU | 54,975 | $710,827 | — |
| PSU | 18,621 | $240,770 | — |
| RSU | 6,207 | $80,257 | — |
| Option | 81,499 | — | $18.19 |
| Option | 117,261 | — | $16.30 |
| Option | 15,485 | — | $76.97 |
| Option | 2,902 | — | $73.20 |
| Option | 7,605 | — | $80.59 |
Per the Outstanding Equity Awards at Fiscal Year-End table in NovoCure Ltd's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2025 proxy (filed April 20, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-30 | Grant or award | — | 1,905 | $11.15 | 461,425 |
| 2026-06-04 | Sale | — | 34,273 | $17.93 | 459,520 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments NovoCure discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $438,750 | $0 | $24,472 | $463,222 |
| Resignation for good reason, no change in control | $438,750 | $0 | $24,472 | $463,222 |
| Change in control and involuntary termination | $1,404,000 | $3,992,448 | $32,629 | $5,429,077 |
| Change in control and resignation for good reason | $1,404,000 | $3,992,448 | $32,629 | $5,429,077 |
Per the Potential Payments Upon Termination or Change in Control table in NovoCure Ltd's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
NovoCure’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Ashley Cordova | Former Chief Executive Officer | $13,198,354 |
| Frank Leonard · this page | Chief Executive Officer | $6,975,329 |
| Christoph Brackmann | Chief Financial Officer | $4,163,398 |
| Uri Weinberg | Chief Medical and Innovation Officer | $4,159,945 |
| Nicolas Leupin | Former Chief Medical Officer | $3,999,041 |
| Michael Puri | Chief Human Resources Officer | $3,933,893 |
Board service
NovoCure board · FY2025How this board is paid
Company policy: NovoCure pays directors a $55,000 cash retainer and $375,000 in equity. As stated in NovoCure's FY2025 proxy.
The full NovoCure compensation record
free company briefThis page is one person within NovoCure's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the NovoCure proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order NovoCure's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NovoCure's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.